1.Long-term survey on reversible uremia in patients with lupus nephritis
Xiaoping LI ; Xionggen LI ; Rengao YE
Chinese Journal of Nephrology 1997;0(06):-
Objective In order to investigate the reversibility of uremia in patients with lupus nephritis(LN). Methods 37 uremic patients with IN who underwent dialysis were treated with a progressive protocol of combined glucocorticoid and cyclophosphamide (CTX) during the last 15 years. Results 83.8% of patients withdrawed from dialysis, with an average withdrawal period of 40.6 ?21.5 months, and with serum creatinine of 179.36 ?88.24 fjiaoVL at least half year after the withdrawal. Conclusion Uremic patients with LN who should be dialysed are not necessarily in end stage of their renal diseases, and those who are indicated for immunosuppressants and probable to be reversed should be treated properly and promptly.
2.Peritoneal protein losses, a novel predictor of cardiovascular diseases in patients on continuous ambulatory peritoneal dialysis
Baochun GUO ; Xinyan JIANG ; Xinzhou ZHANG ; Xiaolei HE ; Xiangyang WANG ; Xue ZHENG ; Yongquan LI ; Xionggen LI
Chinese Journal of Nephrology 2010;26(11):829-833
Objective To study the relationship between cardiovascular diseases (CVD)and 24-h peritoneal protein losses (PPL) in continuous ambulatory peritoneal dialysis (CAPD)patients. Methods One hundred and seventy-eight CAPD patients in our department were enrolled in this study. Their 24-h PPL was measured and other clinical data were recorded at the beginning. Meanwhile, Doppler ultrasound examination was performed. They were then followed-up prospectively for the development of CVD. Results The average of 24-h PPL was (5.0±1.8) g.Patients with diabetic status or preexisting CVD or carotid arteries arteriosclerosis had higher 24-h PPL than those without (t=2.082, P=0.039; t=2.601, P=0.010; t=2.217, P=0.029). 24-h PPL was positively correlated with left ventricular end-diastolic diameter (LVDd), interventricular septal thickness (IVSTd), posterior wall diameter of left ventricle at end-diastolic (LVPWd) and left ventricular mass index (LVMI) (r=0.222, P=0.040; r=0.217, P=0.043; r=0.339, P=0.002; r=0.305, P=0.007). It was negatively correlated with ejection fraction of left ventricle (r=0.221, P=0.040). One hundred and fourteen CAPD patients were prospectively followed-up for at least twelve months. Patients developing CVD were 40.4% and 19.3% for high and low PPL groups respectively (x2=6.035, P=0.014). In the multivariable logistic regression analysis, the 24-h PPL was one of the independent factors for developing CVD. Conclusions There is a significant and independent relationship between 24-h PPL and new cardiovascular events. 24-h PPL may be an important predictor of cardiovascular disease.
3.Effects of cimetidine on platelet function and thrombosis
Changlong LIAO ; Qiyun LI ; Guang XU ; Xionggen LI ; Xinzhou ZHANG ; Wangfan ZHANG
Chinese Journal of Pathophysiology 1989;0(05):-
AIM: To observe the effects of cimetidine(Cim) on platelet function and thrombosis. METHODS: After incubated with Cim in vitro , rat platelets were activated with ADP or thrombin. The platelet aggregation, platelet malondialdehyde(MDA) formation, platelet intracellular free calcium([Ca 2+ ] i), and thromboxane B 2 (TXB 2) were measured. The effects of Cim on electric-induced thrombosis in rat carotid artery were examined. RESULTS: Cim potentiated ADP induced platelet aggregation , increased the thrombin induced [Ca 2+ ] i and MDA formation, decreased TXB 2. Also, Cim shortened the duration of electric-stimulated occlution time in rat carotid artery. CONCLUSION: Cim increased platelet function and accelerated thrombosis.
4.Prevention of hospital-acquired pneumonia with Yupingfeng Powder in patients with acute cerebral vascular diseases: a randomized controlled trial.
Li YAN ; Xianchuan CHEN ; Jian GUO ; Lili QI ; Yiming QIAN ; Xionggen ZHOU
Journal of Integrative Medicine 2010;8(1):25-9
An increase in the incidence rate of hospital-acquired pneumonia (HAP) has a direct influence on prognosis and survival of patients with acute cerebral vascular diseases (ACVD), and how to prevent HAP is a growing concern to clinicians.